Aim: Despite predictions of increased clinical applications, little is known about primary care providers' (PCPs') readiness to apply genomics to patient care. The aim was to assess PCPs' current experience with genetic testing, their assessment of the understandability and clinical utility of information in sample direct-to-consumer reports for genomic assessment of disease risk and warfarin dosing and attitudes toward genomic medicine. Materials & methods: A web-based survey of PCPs who are members of Knowledge Networks' Physician Consulting Network was conducted. Results: Of the 502 respondents (23.3% response rate), most ordered genetic tests infrequently. When presented with the direct-toconsumer genomic testing reports, most believed the reports were understandable, and would be willing to review results with a patient, and many believed the results would be helpful in patient management. Conclusion: Despite limited experience with genetic tests, PCPs are open to helping patients understand genomic information. However, additional physician education is needed.
Incorporating direct-to-consumer genomic information into patient care: attitudes and experiences of primary care physicians Primary care providers (PCPs) are increasingly expected to integrate genomic medicine into patient care [1, 2] . However, this incorporation has been slow due to lack of knowledge and confidence, limited evidence of clinical utility and concerns about privacy and discrimination [2] [3] [4] [5] [6] [7] . Currently, most genetic testing performed is done to look for mutations in single genes associated with Mendelian disorders. Increasingly, testing will focus on variation in a person's entire genome as opposed to information about a single gene variant. This shift is likely to magnify the challenges of incorporating genomic medicine into healthcare [8] .
Due in part to the slow diffusion of genomic medicine into patient care, commercial companies have begun selling tests to predict disease risk and drug response directly to consumers [9] . Although there are few data on utilization, approximately 40% of physicians report being aware of direct-to-consumer (DTC) genetic testing [10, 11] , and consumers' interest is high [12, 13] . Users of DTC tests are motivated by curiosity and an intention to improve health based on genetic predisposition [12, 14] . Several studies document that users share or intend to share DTC results with their physicians [14] [15] [16] . This implies that PCPs increasingly will be asked to explain reports and make medical recommendations based on test results [12] .
Of the available DTC tests, genomic risk profiles for complex diseases (e.g., diabetes and heart disease among others) and pharmacogenetic testing are most likely to demand the attention of PCPs. The medical relevance of the former is questionable as genetic variants identified to date account for only a fraction of the overall genetic contribution to common diseases, and the risk imparted by each variant is small with odds ratios (ORs) in the range of 1.1-1.4 [17] . Although both patients and providers may believe that genetic test results could motivate healthy behavioral changes [14, 18] , the extent to which results lead to behaviors to decrease risk, or to earlier diagnosis, is unclear [19] . Still, consumers receiving such results may seek, expect, or require changes in their medical management, follow-up care, or both.
Pharmacogenetic testing may improve patient care through tailored prescribing of medications [20] . Although over 70 US FDA-approved drugs contain pharmacogenetic information in their labeling, clear action-oriented information is often absent [21] . One exception is warfarin. The FDA updated the drug label in 2007 and 2010 with therapeutic dosing guidelines based on CYP2C9 and VKORC1 genetic test results. However, this recommendation was made despite the lack of prospective studies demonstrating superior outcomes, reduced toxicity or cost savings when using a pharmacogenetic approach to warfarin dosing [20] . This evidentiary gap, in addition to a lack of clinical practice guidelines and insurance reimbursement, may explain future science group physicians' reluctance to adopt pharmacogenetic testing to guide drug therapy [22] .
Despite predictions of increased clinical applications of genomics and evidence that physicians are being asked about DTC testing, little is known about physicians' readiness to apply genomics to patients' care, nor about their opinions about DTC genomic testing. Accordingly, a survey of PCPs practicing in the USA was conducted to assess their responses to reports of DTC genomic testing presented by a hypothetical patient, and their attitudes toward personalized genomics.
Materials & methods
n Survey design The survey was developed by the study team, which includes genetic counselors, physicians (including PCPs) and social science experts with experience in genomic medicine. Questions assessed providers' current experience with ordering genetic tests and their perceived preparation for incorporating genomic medicine into practice. The survey included sample reports adapted from actual reports of two DTC companies offering genomic testing. The first vignette provided a brief description of a hypothetical patient and a report excerpt presenting the patient's risk for several common complex disorders based on genotype, and the second vignette provided another report excerpt presenting information on the hypothetical patient's sensitivity to warfarin based on VKORC1 genotype (Figure 1) .
After reading each report, respondents were asked about factors related to readiness to incorporate the type of results presented in the report into patient care, including willingness and confidence to discuss results, understandability and clinical utility of the reports and previous exposure to such reports (using Likert scales). They were also asked attitudinal questions about various aspects of genomic medicine using Likert scale responses. Finally, the survey included questions about sociodemographics, experience with genetic testing and prior genetics education. For the sociodemographic questions, participants were given a 'do not wish to respond' option for the age, gender and race items.
The survey was piloted on five internists and modifications were made according to their recom mendations. The physicians piloting the survey believed that most PCPs would be unfamiliar with the term 'genomic testing', and they recommended that we use the terms 'genetic testing', 'genetic risk assessment' or 'genetic scan'. They further suggested that we explicitly state that respondents need not be familiar with genetic testing for disease risk or drug metabolism in order to complete the survey. Through piloting, we found that the survey took approximately 20 min to complete. A copy of the survey instrument is included in the Supple mentary material (see www.futuremedicine.com/doi/ suppl/10.2217/pme.12.80).
n Survey population The web-based survey was delivered by the survey research firm Knowledge Networks (KN). KN sampled members of its Physician Consulting Network (PCN), an opt-in panel consisting of physicians invited to join from large national databases (e.g., American Medical Association [AMA] Masterfile). The PCN has been used in other published research assessing physician behavior [101] , and data from KN comparing their PCN primary care sample with the AMA Masterfile indicates that their profile represents US PCPs in terms of region of practice and practice type, but has a slightly older sample and more male participants (80 compared with 70% male in the AMA Masterfile).
n Recruitment In August 2011, an email invitation including the survey URL was sent to a random sample of 2155 PCN panel members who listed family medicine or general internal medicine as their primary specialty. To reduce response bias, the email did not specify that the survey was about genetics. Participants who clicked the URL were taken to an online consent form, which then described the topic of the survey. Two email reminders were sent to nonresponders. Respondents were paid US$30 after completing the survey.
n Analysis First, frequencies were calculated to assess the distribution of responses to the main survey items. Next, bivariate linear or logistic regressions (depending on whether the variables were linear or dichotomous) were estimated to examine associations between key variables, such as frequency of ordering genetic tests and attitudinal responses to the testing scenarios. To examine differences between the two scenarios, tests of differences in proportions (z-tests) were conducted. These tests were one tailed given the expectation that providers would have greater familiarity with the pharmacogenetics scenario. Finally, bi variate linear and logistic regressions were estimated to explore differences in the main outcomes by physician specialty.
future science group Open-ended responses were coded by two authors. To analyze management changes physicians would make based on the DTC report, responses were grouped into specific or general categories, and responses were coded thematically. Management changes were coded as 'specific' if respondents included a specific disease in their recommendation as opposed to general recommendations (e.g., modify diet and lifestyle) without mention of a specific disease. Changes were coded as 'responding to an increased risk' or 'responding to a decreased risk' respectively if the changes were in response to the risk for Alzheimer's disease, glaucoma or obesity (disorders for which risk was increased according to the report) or diabetes, heart attack or lung or prostate cancer (disorders for which risk was decreased according to the report). Changes that included responses to both types of risk were coded as mixed.
The study was approved by the Institutional Review Boards of the University of Pennsylvania (PA, USA) and the Coriell Institute for Medical Research (NJ, USA).
Results

n Participants
The survey was sent to 2155 physicians (777 family medicine and 1378 internal medicine physicians). Five hundred and twenty three physicians completed the survey, 502 of whom were qualified (21 respondents were excluded because they Imagine that a 52-year-old man returns to your office for an annual evaluation and check of his mild hypertension, which is well controlled with a diuretic. After you perform a physical examination with no unusual findings, he asks you to review his 'genetic scan', which he obtained from a company that advertises on the internet. He states that the interpretation provided by the company says that he may be at increased risk for several disorders, and suggests that he discuss this with his physician. The summary of the results of his genetic scan are as follows:
Now imagine that this same patient develops atrial fibrillation and you decide to initiate treatment with warfarin. The patient's genome scan also reports on the rs9923231 sequence variant in the VKORC1 gene on chromosome 16 and several other sequence variants. These genetic sequence variants influence warfarin sensitivity for individuals of European descent. The patient's genome scan included the following information:
If you ever require warfarin therapy, the following information may be useful to your physician for estimating the dose that you may need. future science group did not indicate their specialty or because they did not currently see patients). The survey was therefore completed by 23.3% of physicians contacted (24.1% of family practitioners and 22.9% of internists). Sociodemographic characteristics of respondents is included in table 1. Approximately two out of three of respondents specialized in internal medicine and one out of three in family medicine. Nearly all respondents had been in practice for at least 10 years, reported seeing patients 4 or more days per week, seeing at least ten patients each day and maintained private office-based practices. The majority of respondents were male, white and 50 years of age or older. There were no significant differences between respondents and nonrespondents with regard to gender and age, the only variables available from KN about nonrespondents.
n Experience with genetics Only 50% of respondents ordered a genetic test more than once a year, and only 16% ordered tests once a week or more. There was no statistically significant association between either age or years in practice and frequency of genetic test ordering (all p-values > 0.05). Of the 361 respondents who indicated which test(s) they most frequently ordered, slightly under half indicated that BRCA testing was most frequently ordered, followed by DNA testing for hemochromatosis (table 2) .
A total of 58% of respondents reported feeling confident in interpreting genetic test results (table 2) . A total of 20% had no genetics education, while 56% had a genetics course in medical school; only 22% felt their training in genetics was sufficient to work with their patients who have had genetic testing. Physicians ordering genetic tests at least once a month were more likely to feel confident interpreting test results (p < 0.001), and to report that their training in genetics was 'sufficient' (p < 0.001).
n DTC genetic testing scenarios Most respondents believed the complex disease report was understandable and would be willing to discuss it with the patient (Figure 2) . As an assessment of clinical utility, 40% agreed that such results would be helpful in patient management. A total of 49% of respondents agreed that this kind of testing will be common place in the next 5 years. Respondents who ordered genetic tests at least once a month were significantly more likely to agree that: the report is understandable (p = 0.007); they would feel confident discussing results (p = 0.024); such test results are helpful in patient management (p = 0.003); and they would order such testing for their patients (p = 0.005).
When presented with the DTC test report containing results for warfarin sensitivity, 83% of respondents agreed the report is understandable, and 88% would be willing to review the results with the patient (Figure 2) . Although 70% believed the results would be helpful in managing the patient and therefore clinically useful, only 32% would order such testing before initiating therapy.
Nearly every physician (97%) reported starting a patient on warfarin in the past 2 years; however, most (89%) had not ordered a pharmacogenetic test to guide warfarin dosing. When asked in an open-ended question why they had not ordered pharmacogenetic testing before initiating warfarin therapy, 34% reported testing was not indicated, 27% were unaware of testing, 15% indicated testing was unavailable, 14% cited cost or lack of insurance coverage, and 7% said it was not standard of care. Comparing genetic testing for susceptibility to common complex diseases with pharmocogenetic testing, providers were significantly more likely to agree that: the pharmaco genetic test report was understandable (p = 0.003); they would feel confident discussing pharmacogenetic results (p < 0.001); and pharmacogenetic results would be helpful in managing the patient (p < 0.0001).
n Use of genomic test results in management decisions After viewing the complex disease report, 43% of respondents indicated they would be likely or very likely to change the management of the hypothetical patient. Of the 213 respondents who would change patient management, approximately one-third did not mention the disorders they would address (in an open-ended question), and gave nonspecific responses (table 3) . Approximately one-third of respondents who would use the genomic results in management indicated they would address Alzheimer's disease and/or glaucoma risk (for which increased risk was indicated in the report). For Alzheimer's disease risk, respondents reported that they would conduct more frequent screening for early dementia, provide recommendations for risk reduction, or educate the patient about increased Alzheimer's disease risk; several respondents would recommend ordering imaging (e.g., CT, MRI or PET scans). Respondents also indicated they would address the increased glaucoma risk through more frequent eye exams. The other one-third would address the risk of cardiovascular disease or Type 2 diabetes (for which decreased risk was indicated) by recommending lifestyle changes including increased exercise, weight loss and smoking cessation. Some would also recommend checking blood glucose levels regularly, lowering lipid levels or performing stress tests. No respondent would reduce screening in response to the reported reduced disease risk. Respondents were more likely to state they would change patient management when they indicated the report was understandable (OR: 2.26; p < 0.001) or that they felt confident discussing results (OR: 3.54; p < 0.001).
n Experience with DTC genetic testing & attitudes towards genomic testing in general Thirty-five respondents (7%) indicated that they had previously seen a patient's DTC genetic risk assessment report, and only two reported that they personally had been tested.
Although 40% of respondents believed that genetic testing for common disease risk currently offers clinically useful information, 57% believed that genomic medicine will improve clinical outcomes within 5 years (table 4) . A minority of respondents (45%) felt knowledgeable about the genetic basis of common diseases or about pharmacogenetics (35%), and only future science group 37% reported being ready to take care of patients who have had genetic testing for complex diseases. Although 72% of respondents believed that patients will be interested in having genetic testing, only 46% agreed that it will motivate patients to adopt healthy behaviors. Sixty-eight percent reported being concerned that genetic testing will lead to insurance discrimination. There were no significant differences in responses to the scenarios or attitudes about genomic testing by respondents' specialty.
Discussion
We found that PCPs share the excitement expressed in the popular media and by members of the general public that genomic advances will eventually improve clinical outcomes [23, 24] . They also share some of the public's concerns about genomic medicine, especially with regard to potential insurance discrimination [25] . Although most respondents are willing to try to help patients understand genomic information, many remain skeptical both about their ability to interpret genomic information and the clinical utility of genomic information.
Consistent with the findings of other research [26, 27] , the majority of PCPs we surveyed do order genetic tests, albeit infrequently. Tests for mutations in BRCA1 and BRCA2 are most commonly ordered, potentially attributed in part to Myriad Genetics' (UT, USA) marketing efforts to both healthcare consumers and providers [28, 29] . Although physicians who order genetic tests infrequently are less confident in their ability to interpret the results of those tests, we cannot ascertain if lack of confidence leads to ordering fewer tests, or if less exposure to genetic testing reports results in feeling less confident.
Despite limited previous experience with genetic testing, most respondents would be willing to discuss a hypothetical patient's DTC test results, agreed that the test reports (especially the pharmacogenetic report) are understandable and would be confident discussing the reported results. This finding is counter to other research showing that physicians generally do not feel prepared to discuss DTC testing with patients [11] . In the study by Powell et al., partici pants were not presented with a sample test report [11] . Therefore, perceived lack of preparation could relate to lack of familiarity with the types of reports DTC companies provide. By contrast, our study included a sample report which most participating providers believed to be understandable, likely contributing to providers' confidence. In addition, providers 
Modifications reported n (%) Example
None 289 (57.6) NA Nonspecific 59 (11.8) "Emphasize regular exercise, proper nutrition, weight management and recommend medications if necessary" Specific only to Alzheimer's disease and/or glaucoma risk (increased risk stated in report) 68 (13.6) "Baseline and periodic rescreening using an Alzheimer's screening tool; place reminder in chart to prompt me to remind him regarding annual eye exams including intraocular pressure testing" Specific only to diabetes, heart disease and/or cancer risk (decreased risk stated in report) 72 (14.3) "I would look strongly on the patient's risk for heart disease and diabetes and may start treatment for these disorders earlier. I would also counsel more for weight loss and be more vigilant in ordering screening and monitoring of blood sugar and lipids"
Specific to disorders with both increased and decreased risk 14 (2.8) "Do mini mental exam to check for early sign of dementia, monitor blood sugar and cholesterol on a regular basis" †
Modifications were reported on open-field responses and categorized by the authors (n = 502). NA: Not applicable.
future science group may have felt more confident interpreting results for the disorders included in the report as they are likely addressed in routine risk assessment and counseling, albeit not using genetic testing. As reported by Stanek et al., most respondents held positive views towards pharmacogenetic testing, believing that such testing, at least in theory, would be helpful in managing patients [30] . This is surprising considering that few respondents had ever ordered genetic testing before starting a patient on warfarin, and most would be reluctant to use such testing in hypothetical patients. Stanek et al. have suggested that although physicians are receptive to future use of pharmocogenomic testing, their failure to order testing relates to more practical barriers such as lack of awareness of how and when to order tests [30] . In our study, respondents cited those barriers, and also frequently believed that such testing was not indicated, possibly reflecting clinicians' confidence in traditional approaches to warfarin management. Findings from previous surveys have documented providers' concerns about the uncertainty and ambiguity of genomic findings in general [18] and skepticism about the clinical benefits of warfarin pharmacogenetic testing in particular [31] .
Compared with the pharmacogenetic scenario results, respondents felt less prepared to deal with common disease risk information. Despite this, 43% of respondents cited modifications they would make to their management of the hypothetical patient based only on small relative risks of disease. Few other studies are available reporting on what actions PCPs actually take or might take in response to patients' DTC testing for risk of common diseases. One study reported that only one of five PCP who had patients bring in reports of DTC testing modified management in response to test results [11] . Another study found that the majority of medical students would recommend increased screening in response to DTC test results on a hypothetical patient presenting with test results indicating a modestly increased risk of either breast cancer or macular degeneration [32] .
Of concern, some respondents would increase screening in response to a reported decreased disease risk, implying confusion about the risk data supplied. This finding supports previously reported concerns about provider misunderstanding of probabilistic risk information [33, 34] , and provider response to DTC testing by ordering unnecessary follow-up procedures [33] . Although most recommendations the respondents made followed general public health guidelines (lose weight, stop smoking and so on), a few providers would order tests that were not indicated clinically based on the sample report supplied.
The need for additional physician education about the clinical applications of new genomic technologies and knowledge is unquestioned [2, [35] [36] [37] . To date, genetic education has focused on diseases with Mendelian inheritance, ignoring the contribution of genetic variation throughout the genome to complex disease risk and drug response [36] . In addition to traditional educational future science group approaches through didactic courses in medical school or CME courses, several studies have explored more innovative ways to expand PCPs knowledge of genomics. One somewhat controversial educational approach to increase provider knowledge of and understanding of probabilistic results from common disease testing is offering physicians their own genotyping [27, 32, 34] . Despite these innovative approaches to education, neither personal experience nor clinician education alone is likely to foster widespread adoption of genomic medicine. Clinical practice guidelines, evidencebased outcomes data, and evidence of the efficacy of protections against breaches of confidentiality and discrimination, such as those addressed by the Genetic Information Nondiscrimination Act of 2008, will be needed [11, 38] . Our study has several limitations. First, the sample was composed of members of Knowledge Network's PCN, who are slightly older and more male compared with US PCPs in general. Second, our participation rate was low, but typical of the response rate to other web-based surveys of physicians [39] , and far exceeding the response rate of other physician surveys on similar topics [11, 30, 40] . Third, with any survey, issues of response bias should be considered, where respondents are different in important ways from nonrespondents; in this study, participation was unlikely to be biased based on interest in or knowledge about genetics since providers were not informed of the topic during recruitment and respondents were representative of the PCN panel. Fourth, we used hypothetical scenarios to understand how providers might respond to an actual patient. Responses to hypothetical vignettes may not mirror actual behavior [41, 42] . In addition, the scenarios and report excerpts were short and relatively un complicated. Physicians may respond differently to reports that are many pages long, that include actual genotypes or SNP numbers, or that include results for hundreds of conditions and traits. Finally, we did not provide a definition of genetic testing, so providers may have interpreted this term in diverse ways.
However, an open-ended question about genetic tests ordered suggests respondents were using similar and accepted definitions of genetic testing.
Conclusion
Despite these limitations, our results provide insight on how prepared PCPs are for incorporating personalized genomic information into patient care. Although most of the PCPs surveyed claimed to be fairly confident discussing results and found the reports understandable, some would make recommendations that are not justified by test results, particularly the very small increase in disease risk or the dearth of data supporting tests' clinical utility. More research is needed on how providers can effectively provide recommendations that incorporate both genetic and nongenetic risk factors [43] . Additional research is also needed on how physicians react to actual patient genomic testing information, and on clinical and behavioral outcomes of testing.
Future perspective
For over a decade, there have been predictions of a genetics revolution leading to a new era of personalized medicine in which knowledge of a patient's personal genomics will reveal predispositions or guide personalized treatments, leading patients and physicians to appropriate actions to reduce morbidity and mortality [44] . Unfortunately, outside of oncology, most patients have not been able to benefit from genetically targeted treatments and prevention. Ultimately, the extent to which genomic medicine diffuses into patient care is likely to depend on sufficient evidence of improved outcomes compared with current practices. As data on the comparative effectiveness of genomically informed interventions are gathered, physicians will need to be educated so they can interpret genomic data, including data obtained from DTC companies and educate patients about their genetic risk [45] .
future science group
Executive summary
Background
Genomic testing to predict disease risk and medication response is being obtained by healthcare consumers through direct-to-consumer (DTC) genetic testing companies. People obtaining such testing are likely to seek guidance from their primary care physicians about their DTC test results. Practicing physicians providing primary care to adults only infrequently order genetic tests and thus lack experience with interpreting genomic testing results.
Materials & methods
We conducted a web-based survey of primary care providers (general internists and family practitioners who are members of Knowledge Networks' Physician Consulting Network). The survey assessed physicians' current experience with genetic testing, their assessment of the understandability and clinical utility of information in sample DTC reports for genomic assessment of disease risk and warfarin dosing, and attitudes toward genomic medicine.
Results
If presented by a hypothetical patient with a report about disease risk and medication response obtained from a DTC genetic testing company, most responding physicians would agree to review the report and believed the report to be understandable. Although the majority of responding physicians believe that pharmocogenetic testing results would be helpful in patient management and would feel confident discussing results with patients, few had ever ordered a pharmacogenetic test for warfarin dosing. Physicians feel less well prepared to deal with genomic information relating to the risk of common disease and are skeptical about the clinical utility of genomic information to predict disease risk.
The majority of primary care providers are concerned that genomic medicine will lead to insurance discrimination.
Discussion
